{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-278533","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2026-06-23T12:00:06+00:00","discovered_at":"2026-06-23T12:05:00.249248+00:00","generated_at":"2026-06-23T12:05:55.247395+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Phathom completes enrollment in Phase 2 EoE trial; topline data expected Q4 2026","bullets":["Enrolled 95 adults at 41 US sites in pHalcon-EoE-201 Phase 2 trial of VOQUEZNA for eosinophilic esophagitis.","Patients randomized 1:1 to VOQUEZNA 20 mg or placebo once daily for 12 weeks; optional open-label extension.","Topline results anticipated in Q4 2026; positive data could lead to FDA discussions on pediatric exclusivity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-278533","json":"https://secwatch.observer/filing/0001193125-26-278533.json","markdown":"https://secwatch.observer/filing/0001193125-26-278533.md","text":"https://secwatch.observer/filing/0001193125-26-278533.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526278533/0001193125-26-278533-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526278533/d166684d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T12:05:55.247395+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}